Currently approved but not yet activated NCI-sponsored trials of rituximab.
| NCI | Dose adjusted EPOCH chemotherapy with rituximab in previously untreated aggressive non-Hodgkin's lymphoma |
| SWOG | A randomized phase III trial of ESHAP chemotherapy with or without rituximab for the treatment of relapsed or refractory CD20+ aggressive B cell non-Hodgkin's lymphoma |
| CALGB | Interleukin-2 and anti-CD20 in CD20+ B cell lymphoid malignancies |
| CALGB | Randomized phase III trial of fludarabine/mitoxantrone/dexamethasone (FMD) with concurrent or subsequent administration of rituximab monoclonal antibody |
| ECOG | Rituximab for Waldenström's macroglobulinemia, a phase II pilot study for untreated and previously treated patients |
| Abbreviations: See Table 1. NCI, National Cancer Institute; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ESHAP, etoposide, solumedrol, doxorubicin, cytosine arabinoside, cisplatin. | |
| NCI | Dose adjusted EPOCH chemotherapy with rituximab in previously untreated aggressive non-Hodgkin's lymphoma |
| SWOG | A randomized phase III trial of ESHAP chemotherapy with or without rituximab for the treatment of relapsed or refractory CD20+ aggressive B cell non-Hodgkin's lymphoma |
| CALGB | Interleukin-2 and anti-CD20 in CD20+ B cell lymphoid malignancies |
| CALGB | Randomized phase III trial of fludarabine/mitoxantrone/dexamethasone (FMD) with concurrent or subsequent administration of rituximab monoclonal antibody |
| ECOG | Rituximab for Waldenström's macroglobulinemia, a phase II pilot study for untreated and previously treated patients |
| Abbreviations: See Table 1. NCI, National Cancer Institute; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; ESHAP, etoposide, solumedrol, doxorubicin, cytosine arabinoside, cisplatin. | |